Andrea Amerio, Luca Magnani, Gabriele Arduino, Fabio Fesce, Renato de Filippis, Alberto Parise, Alessandra Costanza, Khoa D Nguyen, Daniele Saverino, Domenico De Berardis, Andrea Aguglia, Andrea Escelsio, Gianluca Serafi, Pasquale De Fazio, Mario Amore
Recent evidence suggests a possible relationship between the immune system and schizophrenia spectrum disorders (SSDs), as neuroinflammation appears to play a role in major psychiatric conditions. Neuroinflammation is as a broad concept representing a physiological protective response to infection or injury, but in some cases, especially if chronic, it may represent an expression of maladaptive processes, potentially driving to clinical dysfunction and neurodegeneration. Several studies are concurrently highlighting the importance of microglia, the resident immune cells of the central nervous system, in a huge number of neurodegenerative diseases, including multiple sclerosis, Alzheimer's and Parkinson's diseases, as well as SSDs...
November 28, 2023: Current Neuropharmacology
Guangcheng Zhong, Xinyue Wang, Jiaqi Li, Zhouyuan Xie, Qiqing Wu, Jiaxin Chen, Yiyun Wang, Ziying Chen, Xinyue Cao, Tianyao Li, Jinman Liu, Qi Wang
Neurodegenerative diseases encompass a collection of neurological disorders originating from the progressive degeneration of neurons, resulting in the dysfunction of neurons. Unfortunately, effective therapeutic interventions for these diseases are presently lacking. Copper (Cu), a crucial trace element within the human body, assumes a pivotal role in various biological metabolic processes, including energy metabolism, antioxidant defense, and neurotransmission. These processes are vital for the sustenance, growth, and development of organisms...
November 15, 2023: Current Neuropharmacology
Peng-Fei Cheng, Yuan-He, Meng-Meng Ge, Da-Wei Ye, Jian-Ping Chen, Jin-Xi Wang
Humans have long been combating chronic pain. In clinical practice, opioids are first- choice analgesics, but long-term use of these drugs can lead to serious adverse reactions. Finding new, safe and effective pain relievers that are useful treatments for chronic pain is an urgent medical need. Based on accumulating evidence from numerous studies, excess reactive oxygen species (ROS) contribute to the development and maintenance of chronic pain. Some antioxidants are potentially beneficial analgesics in the clinic, but ROS-dependent pathways are completely inhibited only by scavenging ROS directly targeting cellular or subcellular sites...
October 25, 2023: Current Neuropharmacology
Xing Wang, Jun Zheng, Yuqi Chen, Chao You, Lu Ma
BACKGROUND: Patients with previous strokes are at a higher risk of stroke recurrence. Current guidelines recommend a range of low-density lipoprotein cholesterol (LDL-C)-lowering treatments to reduce the risk of recurrent stroke. However, the optimal agent for decreasing LDL-C to lower the risk of recurrent stroke remains unclear. This study aimed to assess the relative effects of various LDL-C -lowering agents for secondary stroke prevention. METHODS: Several databases were searched from inception up to 2022...
October 20, 2023: Current Neuropharmacology
Zhiyong Gao, Meihong Xiu, Jiahong Liu, Fengchun Wu, Xiangyang Zhang
BACKGROUND: It has been hypothesized that smoking is associated with the severity of negative symptoms. Until now, no studies have investigated whether the impact of smoking on negative symptoms is dependent on antioxidants. This study was designed to evaluate the effect of smoking on therapeutic response and total antioxidants capacity (TAOC) in antipsychotic-naïve first-episode (ANFE) patients. METHODS: The severity of the patient's symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS)...
October 19, 2023: Current Neuropharmacology
Jenny Valentina Garmendia, Claudia Valentina De Sanctis, Viswanath Das, Narendran Annadurai, Marián Hajduch, Juan Bautista De Sanctis
Neurodegenerative disease (ND) incidence has recently increased due to improved life expectancy. Alzheimer's (AD) or Parkinson's disease (PD) are the most prevalent NDs. Both diseases are poly genetic, multifactorial and heterogenous. Preventive medicine, a healthy diet, exercise, and controlling comorbidities may delay the onset. After the diseases are diagnosed, therapy is needed to slow progression. Recent studies show that local, peripheral and age-related inflammation accelerates NDs' onset and progression...
October 17, 2023: Current Neuropharmacology
David Zarate-Lopez, Ana Laura Torres-Chávez, Alma Yadira Gálvez-Contreras, Oscar Gonzalez-Perez
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with increased prevalence and incidence in recent decades. Its etiology remains largely unclear, but it seems to involve a strong genetic component and environmental factors that, in turn, induce epigenetic changes during embryonic and postnatal brain development. In recent decades, clinical studies have shown that inutero exposure to valproic acid (VPA), a commonly prescribed antiepileptic drug, is an environmental factor associated with an increased risk of ASD...
October 16, 2023: Current Neuropharmacology
Georgia E Hodes, Debra Bangasser, Ioannis Sotiropoulos, Nikolaos Kokras, Christina Dalla
Neuropsychiatric disorders, which are associated with stress hormone dysregulation, occur at different rates in men and women. Moreover, nowadays, preclinical and clinical evidence demonstrates that sex and gender can lead to differences in stress responses that predispose males and females to different expressions of similar pathologies. In this curated review, we focus on what is known about sex differences in classic mechanisms of stress response, such as glucocorticoid hormones and corticotrophin-releasing factor (CRF), which are components of the hypothalamicpituitary- adrenal (HPA) axis...
October 5, 2023: Current Neuropharmacology
Mattia I Gerin, Essi Viding, Vanessa B Puetz, Diana J N Armbruster-Genc, Georgia Rankin, Eamon J McCrory
BACKGROUND: Childhood maltreatment is associated with altered neurocognitive functioning, which is thought to reflect, in part, adaptation to early adverse environmental experiences. However, we continue to lack a precise mechanistic understanding linking atypical neurocognitive processing with social functioning and psychiatric outcomes following early adversity. OBJECTIVE: The present work investigated interpersonal problem-solving, resting-state functional connectivity (rsFC), and mental health symptoms in adolescents with documented maltreatment experience and explored whether altered neural function contributes in part to poorer social functioning...
October 5, 2023: Current Neuropharmacology
Aurora Zanghì, Diana Ferraro, Graziella Callari, Paola Valentino, Franco Granella, Francesco Patti, Giacomo Lus, Simona Bonavita, Maria Claudia Moretti, Carlo Avolio, Emanuele D'Amico
The intervals between two courses of anti CD20 therapies in the COVID19 pandemic era provided the opportunity to individually delay therapy, known as extended interval dosing (EID). <P> Materials and Methods: We collect real-world data on patients with primary progressive MS (PPMS) treated with Ocrelizumab (OCR) during the COVID'19 pandemic. The observation period in which the standard interval dosing (SID) or EID occurred (always a maintenance cycle, 600 mg) was from January 2020 to June 2021. All patients had two infusions during the observation period...
October 2, 2023: Current Neuropharmacology
Michel Sabé, Chaomei Chen, Wissam El-Hage, Arnaud Leroy, Guillaume Vaiva, Silvia Monari, Natacha Premand, Javier Bartolomei, Stefano Caiolo, Andreas Maercker, Robert H Pietrzak, Marylène Cloître, Stefan Kaiser, Marco Solmi
We conducted a scientometric analysis to outline clinical research on posttraumatic stress disorder (PTSD). Our primary objective was to perform a broad-ranging scientometric analysis to evaluate key themes and trends over the past decades. Our secondary objective was to measure research network performance. We conducted a systematic search in the Web of Science Core Collection up to 15 August 2022 for publications on PTSD. We identified 42,170 publications published between 1945 and 2022. We used CiteSpace to retrieve the co-cited reference network (1978-2022) that presented significant modularity and mean silhouette scores, indicating highly credible clusters (Q = 0...
September 28, 2023: Current Neuropharmacology
Antonia Bendau, Moritz Bruno Petzold, Jan Kaminski, Jens Plag, Andreas Ströhle
The beneficial impact of physical activity on preventing and treating mental disorders has captured growing (research) interest. This article aims to provide a concise overview of essential evidence regarding the effectiveness and underlying mechanisms of physical activity for individuals with mental disorders clustered as "stress-related" conditions. Empirical findings (e.g., longitudinalprospective studies, interventional randomized-controlled-trials, reviews, meta-analyses) regarding the effects of physical activity in the prevention and treatment of stress-related mental disorders are summarized...
September 27, 2023: Current Neuropharmacology
Amit Lazarov, Nira Liberman, Reuven Dar
The Seeking Proxies for Internal States (SPIS) model of obsessive-compulsive disorder (OCD) explains symptoms of OCD as stemming from attenuated access to internal states, which is compensated for by using proxies, which are indices of these states that are more discernible or less ambiguous. Internal states in the SPIS model are subjective states that are not accessible to others, encompassing physiological states, motivations, preferences, memories, and emotions. Compensatory proxies in OCD include fixed rules and rituals as well as seeking and relying on external information...
September 21, 2023: Current Neuropharmacology
Massimo Allegri
No abstract text is available yet for this article.
September 21, 2023: Current Neuropharmacology
Wesley Dawison de Lima, Michael Douglas da Silva, Eurico de Souza Costa, Francisco Irochima Pinheiro, Eduardo Pereira de Azevedo, Ricardo Ney Cobucci, José Rodolfo Lopes de Paiva Cavalcanti, Fausto Pierdoná Guzen
Zolpidem is a non-benzodiazepine hypnotic drug that works as a positive modulator of Gamma-Amino Butyric Acid-A (GABA-A) receptors, with high selectivity for α1 subunits. Given this selective binding, the drug has a strong hypnotic activity. Social isolation during the SARS-CoV-2 pandemic has contributed to increased rates of anxiety, depression, and insomnia. As a result, studies have pointed to a possible increase in the indiscriminate use of drugs with sedative effects, such as Zolpidem, during the pandemic...
September 20, 2023: Current Neuropharmacology
Meihong Xiu, Lei Zhao, Qianqian Sun, Xiaoe Lang
BACKGROUND: Evidence for the efficacy of a low dose of olanzapine (OLA) in combination with antidepressants has been limited and without positive trials in first-episode (FE) patients with schizophrenia (SCH). This study aimed to compare the efficacy in treating negative and depressive symptoms between those FE patients with SCH treated with a combination of OLA plus sertraline and those treated with OLA monotherapy. METHODS: One hundred and ninety-six first-episode and drug naïve patients with SCH were randomized to receive low-dose OLA (7...
September 13, 2023: Current Neuropharmacology
Lucia Caffino, Giorgia Targa, Anne Stephanie Mallien, Francesca Mottarlini, Beatrice Rizzi, Judith R Homberg, Peter Gass, Fabio Fumagalli
BACKGROUND: The mechanisms underlying the action of lithium (LiCl) in bipolar disorder(BD) are still far from being completely understood. Previous evidence has revealed that BD is characterized by glutamate hyperexcitability, suggesting that LiCl may act, at least partially, by toning down glutamatergic signaling abnormalities. OBJECTIVE: In this study, taking advantage of western blot and confocal microscopy, we used a combination of integrative molecular and morphological approaches in rats exposed to repeated administration of LiCl at a therapeutic dose (between 0...
September 13, 2023: Current Neuropharmacology
Laura A Bradfield, Serena Becchi, Michael D Kendig
Individuals often learn how to perform new actions for particular outcomes against a complex background of existing action-outcome associations. As such, this new knowledge can interfere or even compete with existing knowledge, such that individuals must use internal and external cues to determine which action is appropriate to the current situation. The question thus remains as to how this problem is solved at a neural level. Research over the last decade or so has begun to determine how the brain achieves situation-appropriate action selection...
September 13, 2023: Current Neuropharmacology
Enzo Pérez-Valenzuela, Roger Hudson, Taygun Uzuneser, Marta De Felice, Hanna Szkudlarek, Walter Rushlow, Steven R Laviolette
Cannabis has shown therapeutic potential in mood and anxiety-related pathologies. However, the two primary constituents of cannabis, cannabidiol (CBD) and Δ-9-tetrahydrocannabinol (THC) produce distinct effects on molecular pathways in neural circuits associated with affective disorders. Moreover, it has been proposed that the combination of THC: and CBD may have unique synergistic properties. In the present study, the effects of a 1:100 THC: CBD ratio edible formulation were tested in behavioural, neuronal and molecular assays for anxiety and depressive-like endophenotypes...
September 13, 2023: Current Neuropharmacology
Sirin Zhang, Juan Mena-Segovia, Nadine K Gut
BACKGROUND: The pedunculopontine nucleus (PPN) maintains a bidirectional connectivity with the basal ganglia that supports their shared roles in the selection and execution of motor actions. Previous studies identified a role for PPN neurons in goal-directed behavior, but the cellular substrates underlying this function have not been elucidated. We recently revealed the existence of a monosynaptic GABAergic input from the PPN that inhibits dopamine neurons of the substantia nigra. Activation of this pathway interferes with the execution of learned motor sequences when the actions are rewarded, even though the inhibition of dopamine neurons did not shift the value of the action, hence suggesting executive control over the gating of behavior...
September 11, 2023: Current Neuropharmacology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.